Lukas Scheibler - Apr 4, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
CHIEF INNOVATION OFFICER
Signature
/s/ David Watson, attorney-in-fact for Lukas Scheibler
Stock symbol
APLS
Transactions as of
Apr 4, 2022
Transactions value $
-$151,059
Form type
4
Date filed
4/5/2022, 04:08 PM
Previous filing
Apr 4, 2022
Next filing
Apr 6, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $48.5K +3.5K +6.71% $13.85 55.7K Apr 4, 2022 Direct F1
transaction APLS Common Stock Sale -$45.7K -818 -1.47% $55.84 54.9K Apr 4, 2022 Direct F1, F2
transaction APLS Common Stock Sale -$81.7K -1.44K -2.62% $56.86 53.5K Apr 4, 2022 Direct F1, F3
transaction APLS Common Stock Sale -$72.2K -1.25K -2.34% $57.81 52.2K Apr 4, 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -3.5K -6.55% $0.00 50K Apr 4, 2022 Common Stock 3.5K $13.85 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from 10B5-1 trading plan.
F2 The sale price range within $1.00. Max. $55.21 - Min. $56.13
F3 The sale price range within $1.00. Max. $56.34 - Min. $57.22
F4 The sale price range within $1.00. Max. $57.37 - Min. $58.29.
F5 This represents a stock option grant made on 02/08/2019 that vests as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.